The Vera Bradley Foundation Endowed Chair in Breast Cancer Innovation, Professor of Microbiology and Immunology, Director Brown Center for Immuno-Oncology and Vaccine Immunotherapy, The Indiana ...
Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 ...
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells. Blocking CTLA-4 with a specific antibody is an ...
Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer ...
Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 ...
Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: A case-control study with translational correlates. Predictive factors for cardiac events following concurrent ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Researchers at Salk Institute for Biological Studies ...
WALTHAM, Mass., May 31, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for ...
Immune checkpoint inhibitors (ICIs), such as anti-CTLA-4 antibodies, are widely used in cancer immunotherapy. CTLA-4 blockers such as Yervoy (ipilimumab, Bristol Myers Squibb Co.) stimulate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results